Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond

Sonia M. Seng; Che Kai Tsao; Matthew D. Galsky; William K. Oh

doi:10.1016/j.ddstr.2011.02.001

Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond

Sonia M. Seng, Che Kai Tsao, Matthew D. Galsky, William K. Oh

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Prostate cancer is the second most common cancer and the fifth most common cause of cancer deaths in men worldwide. Before docetaxel chemotherapy, no single agent demonstrated a survival advantage for men with metastatic castration resistant prostate cancer (mCRPC). However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. In this review, we examine promising front-line docetaxel combination therapies for chemotherapy naïve patients and novel cytotoxic chemotherapies for patients with progressive disease. We will also highlight a clinical trial utilizing a genome based approach to evaluate the efficacy of a fourth generation platinum, satraplatin, in patients with sporadic BRCA deficient prostate cancers.

Original language	English
Pages (from-to)	17-22
Number of pages	6
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	7
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ddstr.2011.02.001
State	Published - 2010

Access to Document

10.1016/j.ddstr.2011.02.001

Cite this

@article{39c38fb6c5c24c0a9b3245dce1c79e38,

title = "Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond",

abstract = "Prostate cancer is the second most common cancer and the fifth most common cause of cancer deaths in men worldwide. Before docetaxel chemotherapy, no single agent demonstrated a survival advantage for men with metastatic castration resistant prostate cancer (mCRPC). However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. In this review, we examine promising front-line docetaxel combination therapies for chemotherapy na{\"i}ve patients and novel cytotoxic chemotherapies for patients with progressive disease. We will also highlight a clinical trial utilizing a genome based approach to evaluate the efficacy of a fourth generation platinum, satraplatin, in patients with sporadic BRCA deficient prostate cancers.",

author = "Seng, {Sonia M.} and Tsao, {Che Kai} and Galsky, {Matthew D.} and Oh, {William K.}",

year = "2010",

doi = "10.1016/j.ddstr.2011.02.001",

language = "English",

volume = "7",

pages = "17--22",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Ltd.",

number = "1-2",

}

TY - JOUR

T1 - Cytotoxic chemotherapy for castration resistant prostate cancer

T2 - 2010 and beyond

AU - Seng, Sonia M.

AU - Tsao, Che Kai

AU - Galsky, Matthew D.

AU - Oh, William K.

PY - 2010

Y1 - 2010

N2 - Prostate cancer is the second most common cancer and the fifth most common cause of cancer deaths in men worldwide. Before docetaxel chemotherapy, no single agent demonstrated a survival advantage for men with metastatic castration resistant prostate cancer (mCRPC). However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. In this review, we examine promising front-line docetaxel combination therapies for chemotherapy naïve patients and novel cytotoxic chemotherapies for patients with progressive disease. We will also highlight a clinical trial utilizing a genome based approach to evaluate the efficacy of a fourth generation platinum, satraplatin, in patients with sporadic BRCA deficient prostate cancers.

AB - Prostate cancer is the second most common cancer and the fifth most common cause of cancer deaths in men worldwide. Before docetaxel chemotherapy, no single agent demonstrated a survival advantage for men with metastatic castration resistant prostate cancer (mCRPC). However, 2010 has proven to be a landmark year for prostate cancer therapy, with the results of several phase III trials demonstrating improvements in survival with novel therapies. In this review, we examine promising front-line docetaxel combination therapies for chemotherapy naïve patients and novel cytotoxic chemotherapies for patients with progressive disease. We will also highlight a clinical trial utilizing a genome based approach to evaluate the efficacy of a fourth generation platinum, satraplatin, in patients with sporadic BRCA deficient prostate cancers.

UR - http://www.scopus.com/inward/record.url?scp=80055015140&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2011.02.001

DO - 10.1016/j.ddstr.2011.02.001

M3 - Review article

AN - SCOPUS:80055015140

SN - 1740-6773

VL - 7

SP - 17

EP - 22

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 1-2

ER -

Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond

Abstract

Access to Document

Fingerprint

Cite this